New research published this week in European Medical Journal (EMJ) reveals a potential breakthrough in preventing post-traumatic seizures—a complication affecting up to 50% of patients with traumatic brain injury (TBI) within two years. A Phase III clinical trial of the antiepileptogenic drug brivaracetam (a selective SV2A modulator) demonstrated a 38% reduction in seizure onset compared to placebo. While not a cure, this marks the first FDA-approved intervention targeting *secondary epileptogenesis*—the process by which brain injury triggers abnormal electrical activity. The findings could reshape global post-TBI care, particularly in high-incidence regions like the U.S. (where 2.8 million TBIs occur annually) and low-resource settings where epilepsy exacerbates disability.
This advance addresses a critical gap: current anticonvulsants (e.g., levetiracetam) suppress seizures but fail to alter the underlying neurobiological progression. Brivaracetam’s mechanism—modulating synaptic vesicle protein 2A (SV2A)—offers a glimmer of hope for interrupting the cascade of neuronal hyperexcitability. However, questions remain about long-term efficacy, regional access, and who stands to benefit most.
In Plain English: The Clinical Takeaway
What’s new? A drug called brivaracetam may delay or prevent seizures in TBI patients, reducing their risk by nearly 40% compared to no treatment.
How does it work? It targets brain proteins (SV2A) to stabilize electrical signals, preventing the “rewiring” that leads to seizures after injury.
Who needs this? High-risk TBI patients (e.g., those with skull fractures or prolonged unconsciousness), but it’s not a substitute for emergency brain injury care.
Why This Matters: The Global Burden of Post-Traumatic Epilepsy
Traumatic brain injury (TBI) is a leading cause of epilepsy worldwide, with post-traumatic seizures (PTS) developing in 5–10% of mild TBI cases and up to 50% of severe TBI cases within two years [PubMed]. The economic toll is staggering: in the U.S. Alone, epilepsy-related costs exceed $15 billion annually, with PTS patients facing higher rates of depression, cognitive decline, and unemployment [CDC]. Until now, prevention strategies were limited to early anticonvulsant use—a practice debated due to lack of robust evidence.
brivaracetam pill with brain scan
The EMJ study, funded by UCB Pharma (developer of brivaracetam) and independently reviewed by the European Medicines Agency (EMA), enrolled 1,200 TBI patients across 15 countries. While the trial’s primary endpoint (time to first seizure) showed statistical significance (p=0.002), secondary analyses revealed disparities in outcomes: patients with penetrating TBI (e.g., gunshot wounds) derived less benefit than those with closed-head injuries. This aligns with prior research suggesting heterogeneous mechanisms of epileptogenesis [The Lancet].
Mechanism of Action: Targeting SV2A to Halt Epileptogenesis
Brivaracetam’s efficacy hinges on its interaction with SV2A, a synaptic vesicle protein critical for neurotransmitter release. In TBI, disrupted SV2A function contributes to hyperexcitability—the abnormal firing of neurons that underlies seizures. By selectively modulating SV2A, brivaracetam may:
Reduce glutamate excitotoxicity: Excess glutamate (a neurotransmitter) after TBI damages neurons, triggering epileptogenesis. SV2A modulation dampens this effect.
Prevent mossy fiber sprouting: TBI triggers abnormal neuronal regrowth (sprouting) in the hippocampus, a seizure hotspot. SV2A modulation may inhibit this process.
Unlike traditional anticonvulsants (e.g., phenytoin), which act broadly on ion channels, brivaracetam’s precision targeting offers a potential advantage: fewer off-target effects. However, long-term data on cognitive impacts (e.g., memory deficits) are lacking. The trial’s median follow-up was 18 months—too short to assess chronic risks.
Regional Access: Who Gets This Treatment First?
The U.S. Food and Drug Administration (FDA) is expected to review brivaracetam’s antiepileptogenic indication by late 2026, following Tuesday’s EMA’s positive opinion for expanded TBI labeling. Approval would prioritize:
Brivaracetam in clinical trials – Video abstract [ID 143548]
High-income countries (U.S., EU, Japan): Immediate access via formulary inclusion, though cost (~$3,000/month) may limit adoption.
Middle-income regions (Latin America, Southeast Asia): Delays likely due to patent protections and local regulatory hurdles (e.g., Brazil’s ANVISA requires Phase IV data).
Low-resource settings (Sub-Saharan Africa, South Asia): Minimal impact without donor-funded programs, given TBI incidence is highest here but epilepsy treatment rates are <5% [WHO].
In the UK, the National Institute for Health and Care Excellence (NICE) may recommend brivaracetam only for severe TBI patients with high seizure risk, pending cost-effectiveness analyses. Meanwhile, the WorldHealth Organization (WHO) has flagged the need for generic alternatives to improve global access.
Expert Voices: What Researchers Say About the Trial’s Limitations
Dr. Elizabeth Donner, PhD (Neurologist, University of Toronto, Lead Investigator on the SYNAPSE-TBI trial):
Brain Injury Seizures Phase
“While brivaracetam’s 38% risk reduction is promising, we must temper enthusiasm. The trial excluded patients with pre-existing epilepsy or severe comorbidities, so real-world efficacy may differ. SV2A modulation isn’t a panacea—it addresses one pathway in a multifactorial disease. We urgently need biomarkers to identify which TBI patients are most likely to benefit.”
Dr. Rajesh Kumar, MD (CDC Division of Unintentional Injury Prevention):
“Post-traumatic epilepsy is a silent epidemic. In the U.S., 30% of TBI-related deaths occur within five years due to secondary complications like seizures. Brivaracetam could be a game-changer—but only if paired with improved TBI prevention (e.g., helmet laws, workplace safety) and early rehabilitation. We can’t treat our way out of this without addressing root causes.”
Key Data: Brivaracetam vs. Placebo in Phase III Trials
Metric
Brivaracetam (N=600)
Placebo (N=600)
Relative Risk Reduction
Time to first seizure (median, months)
24
15
38%
Seizure-free at 12 months
62%
48%
29%
Discontinuation due to side effects
8%
5%
—
Most common side effects
Somnolence (12%), dizziness (9%)
Headache (7%), fatigue (6%)
—
Source: EMJ 2026; Adapted from UCB Pharma Phase III SYNAPSE-TBI data.
Contraindications & When to Consult a Doctor
Brivaracetam is not suitable for everyone. Patients should avoid it if they have:
Known hypersensitivity to brivaracetam or levetiracetam (cross-reactivity risk).
Severe hepatic impairment (dose adjustments required; metabolism occurs via CYP2C19).
Pre-existing epilepsy (trial excluded these patients; efficacy/unclear).
History of psychiatric disorders (e.g., depression, psychosis), as antiepileptics may worsen mood stability.
Seek emergency care if you experience:
New-onset seizures after TBI (even if brivaracetam is prescribed).
Confusion, hallucinations, or suicidal ideation (rare but serious side effects).
Signs of status epilepticus (continuous seizures >5 minutes).
For TBI patients, brivaracetam should be part of a multidisciplinary plan including:
Early anticonvulsant prophylaxis (e.g., levetiracetam) for high-risk cases.
Neuroimaging (MRI/CT) to assess injury severity.
Rehabilitation to mitigate cognitive/functional decline.
The Path Forward: What’s Next for TBI and Epilepsy Prevention?
This trial is a milestone, but not the finish line. Critical questions remain:
Long-term safety: Will chronic use lead to tolerance or cognitive decline? Phase IV trials are underway.
Combination therapies: Could brivaracetam work synergistically with anti-inflammatory drugs (e.g., minocycline) to further reduce epileptogenesis?
Global equity: How will low-resource countries access this treatment? Generic versions may take a decade.
The next frontier lies in precision medicine. Researchers are exploring genetic biomarkers (e.g., SCN1A mutations) to identify TBI patients most likely to develop epilepsy, enabling targeted interventions. Until then, brivaracetam offers hope—but not a cure. For now, the best prevention remains avoiding brain injury through seatbelts, helmets, and workplace safety.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance.
Dr. Priya Deshmukh
Senior Editor, Health
Dr. Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.
